32 completed. 32 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 32 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebp - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 47 | 2019-04-29 | 2024-03-07 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebo - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 207 | 2019-04-15 | 2024-03-07 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD KHK7791 - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 67 | 2018-12-27 | 2024-03-07 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) KRN23 - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 20 | 2015-01-30 | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 52 | 2014-07-02 | 2024-05-06 |
| Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease PT20, Placebo - Hyperphosphataemia | Phase 2 | Completed | Phosphate Therapeutics | 153 | 2014-05-07 | 2018-01-16 |
| Dose Finding Study to Treat High Phosphate Levels in the Blood. AZD1722, Placebo - Hyperphosphatemia | Phase 2 | Completed | Ardelyx | 162 | 2014-03-01 | 2020-09-14 |
| Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Osvaren Granules, Osvaren film-coated tablets - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Fresenius Medical Care Deutschland GmbH | 61 | 2014-01-01 | 2015-06-10 |
| A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis Lanthanum Carbonate, Calcium Carbonate - Chronic Kidney Disease, Hyperphosphatemia | Phase 2 | Completed | Shire | 63 | 2013-02-15 | 2021-06-10 |
| An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease Placebo, Sevelamer carbonate - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Genzyme, a Sanofi Company | 101 | 2012-05-01 | 2016-07-25 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 23 | 2012-02-01 | 2024-06-18 |
| PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia PA21, Placebo - Chronic Kidney Disease Requiring Hemodialysis | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 183 | 2012-01-11 | 2018-08-23 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 29 | 2011-04-01 | 2024-06-18 |
| Nicotinamide in Hemodialysis Patients With Hyperphosphatemia Nicotinamide - Chronic Kidney Disease, Hemodialysis | Phase 2 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | 252 | 2010-08-01 | 2012-01-18 |
| A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia HS219, Placebo - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | KDL Inc. | 68 | 2009-12-01 | 2015-09-14 |
Showing 20 of 32. Sign in to see all of them.
Hyperphosphatemia (25) · Renal Insufficiency, Chronic (10) · Familial Hypophosphatemic Rickets (7) · Kidney Failure, Chronic (6) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Kidney Diseases (1) · Renal Insufficiency (1)
Metabolic Diseases (32) · Nutritional and Metabolic Diseases (32) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Male Urogenital Diseases (23) · Urogenital Diseases (23) · Urologic Diseases (23) · Kidney Diseases (22) · Chronic Disease (15) · Disease Attributes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Renal Insufficiency (14) · Avitaminosis (8)
Sevelamer (9) · burosumab (6) · lanthanum carbonate (3) · tenapanor (3) · Calcium Carbonate (2) · Niacinamide (2) · SBR 759 (2) · ferric citrate (2) · iron-magnesium hydroxycarbonate (2) · Growth Hormone (1) · Iron (1) · calcium acetate (1) · sucroferric oxyhydroxide (1)
Kyowa Kirin Co., Ltd. (5) · Kyowa Kirin, Inc. (3) · Ardelyx (2) · Bayer (2) · Genzyme, a Sanofi Company (2) · Ineos Healthcare Limited (2) · Novartis Pharmaceuticals (2) · Alebund Pharmaceuticals (1) · Astellas Pharma Inc (1) · Bicetre Hospital (1) · Fresenius Medical Care Deutschland GmbH (1) · KDL Inc. (1) · Keryx Biopharmaceuticals (1) · Kissei Pharmaceutical Co., Ltd. (1) · Kyowa Kirin Pharmaceutical Development Ltd (1)
United States (14) · Japan (9) · United Kingdom (6) · Germany (5) · France (4) · Canada (3) · Poland (3) · China (2) · Italy (2) · Puerto Rico (2) · Sweden (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1)
Amy Zhang, PhD (2) · Alan H Lau, Pharm.D. (1) · Daniel O Young, MD (1) · David P Rosenbaum, PhD (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Julia B Lewis, MD (1) · Li Wang, MD (1) · Maarten Taal, MBChB MD FRCP (1) · Masafumi Fukagawa, MD, PhD (1)
PMID 40576086, PMID 21854503, PMID 25919461, PMID 32721016, PMID 38323855, PMID 39151033, PMID 19776051, PMID 21426511, PMID 24968790, PMID 24975892, PMID 26073451, PMID 28822957, PMID 29617976, PMID 29791829, PMID 30638856, PMID 32651955, PMID 33766811, PMID 34636899, PMID 35236302, PMID 36072994, PMID 38453435, PMID 42044650
2009 (1)